News | August 06, 2025
Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Vasograin Plus represents a major advancement in the treatment of migraine
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
